AbbVie cash flow statement

In fiscal 2025, AbbVie's operations generated $19.03bn of cash; it spent $1.21bn on capital projects, leaving free cash flow of $17.82bn. It returned $11.66bn in dividends and $980m through buybacks.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AbbVie: cash flow statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	6.2	6.3	6.3	3.5	7.5	7.0	10.0	13.4	13.3	17.6	22.8	24.9	22.8	18.8	19.0	20.1
Depreciation and amortisation	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.7	0.8	0.8	0.8	0.8	0.8	0.8
Stock-based pay	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.4	0.8	0.7	0.7	0.7	0.9	1.0	0.9
Capital spending	0.4	0.3	0.5	0.6	0.5	0.5	0.5	0.6	0.6	0.8	0.8	0.7	0.8	1.0	1.2	1.2
Free cash flow	5.9	6.0	5.8	2.9	7.0	6.6	9.4	12.8	12.8	16.8	22.0	24.2	22.1	17.8	17.8	18.9
Free cash flow after stock pay	5.7	5.8	5.6	2.7	6.7	6.2	9.1	12.4	12.3	16.0	21.3	23.6	21.3	16.9	16.9	17.9
Dividends paid	—	—	2.6	2.7	3.3	3.7	4.1	5.6	6.4	7.7	9.3	10.0	10.5	11.0	11.7	12.1
Share buybacks	—	—	0.3	0.7	7.6	6.0	1.4	12.0	0.6	1.0	0.9	1.5	2.0	1.7	1.0	1.5

US$ millions unless shown otherwise. Fiscal quarters.

AbbVie: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	7,048	1,635	5,153	7,024	5,218	3,829	3,436	7,606
Depreciation and amortisation	206	181	186	192	203	188	194	192
Stock-based pay	164	410	179	209	157	444	166	160
Capital spending	291	235	269	381	329	265	322	301
Free cash flow	6,757	1,400	4,884	6,643	4,889	3,564	3,114	7,305
Free cash flow after stock pay	6,593	990	4,705	6,434	4,732	3,120	2,948	7,145

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABBV vs AMGN ABBV vs GILD ABBV vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AbbVie's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AbbVie.